Bullfrog AI (NASDAQ:BFRG – Get Free Report) and Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.
Volatility and Risk
Bullfrog AI has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.
Insider and Institutional Ownership
1.0% of Bullfrog AI shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 33.9% of Bullfrog AI shares are owned by company insiders. Comparatively, 21.1% of Werewolf Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bullfrog AI | 0 | 0 | 0 | 0 | 0.00 |
| Werewolf Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
Werewolf Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 500.00%. Given Werewolf Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Werewolf Therapeutics is more favorable than Bullfrog AI.
Profitability
This table compares Bullfrog AI and Werewolf Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bullfrog AI | N/A | -141.39% | -124.63% |
| Werewolf Therapeutics | -578.80% | -58.83% | -38.45% |
Earnings and Valuation
This table compares Bullfrog AI and Werewolf Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bullfrog AI | $60,000.00 | 312.11 | -$5.36 million | ($0.85) | -2.53 |
| Werewolf Therapeutics | $19.94 million | 4.47 | -$37.37 million | ($1.53) | -1.31 |
Bullfrog AI has higher earnings, but lower revenue than Werewolf Therapeutics. Bullfrog AI is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Werewolf Therapeutics beats Bullfrog AI on 9 of the 14 factors compared between the two stocks.
About Bullfrog AI
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.
About Werewolf Therapeutics
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Bullfrog AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bullfrog AI and related companies with MarketBeat.com's FREE daily email newsletter.
